Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis
BioPharma Dive
Gilead s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple prospects already in clinical testing.
pharminent
April 7, 2026 (Last updated: April 7, 2026)
BioPharma Dive
Gilead s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple prospects already in clinical testing.